Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]:
SEC Accession No. 0000912282-11-000145
Filing Date
2011-03-24
Accepted
2011-03-24 17:17:05
Documents
14
Period of Report
2010-12-31

Document Format Files

Seq Description Document Type Size
1 oncolytics_20f-12312010.htm 20-F 2144436
2 AMENDMENT NO. 2, DATED JANUARY 1, 2011, TO THE EXECUTIVE EMPLOYMENT AGREEMENT BE ex4_17.htm EX-4.17 2357
3 LIST OF SUBSIDIARIES ex8_1.htm EX-8.1 3779
4 CERTIFICATION OF CHIEF EXECUTIVE OFFICER ex12_1.htm EX-12.1 13221
5 CERTIFICATION OF CHIEF FINANCIAL OFFICER ex12_2.htm EX-12.2 12715
6 CERTIFICATION OF CHIEF EXECUTIVE OFFICER ex13_1.htm EX-13.1 7254
7 CERTIFICATION OF CHIEF FINANCIAL OFFICER ex13_2.htm EX-13.2 6133
8 THE REGISTRANT'S MANAGEMENT'S DISCUSSION AND ANALYSIS FOR THE YEAR ENDED DECEMBE ex15_1.htm EX-15.1 488334
9 CONSENT OF ERNST & YOUNG LLP ex15_2.htm EX-15.2 6546
10 oncolytics_logo.jpg GRAPHIC 12620
11 reovirus.jpg GRAPHIC 86821
12 ernstyounglogo.jpg GRAPHIC 6545
13 onco_p1.jpg GRAPHIC 250282
14 onco_p2.jpg GRAPHIC 263488
  Complete submission text file 0000912282-11-000145.txt   3540298
Mailing Address 210 - 1167 KENSINGTON CRES NW CALGARY A0 T2N 1X7
Business Address 1167 KENSINGTON CRES NW SUITE 210 CALGARY ALBERTA CANADA T2N 1X7 ALBERTA CANADA A0 00000 4036707380
ONCOLYTICS BIOTECH INC (Filer) CIK: 0001129928 (see all company filings)

EIN.: 000000000 | Fiscal Year End: 1231
Type: 20-F | Act: 34 | File No.: 000-31062 | Film No.: 11710205
SIC: 2834 Pharmaceutical Preparations